Recent advances in atrial fibrillation and stroke

Neurological Research

Volumn 37, Issue 5, 2015, Pages 381-384

  David Spence, J ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; APIXABAN; DABIGATRAN; HOMOCYSTEINE; RIVAROXABAN; WARFARIN; CYANOCOBALAMIN;

ARTICLE; ATRIAL FIBRILLATION; CARDIOEMBOLIC STROKE; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CYANOCOBALAMIN DEFICIENCY; DEEP VEIN THROMBOSIS; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; LACUNAR STROKE; RECURRENT DISEASE; TRANSIENT ISCHEMIC ATTACK; VASCULITIS; ADULT; AGED; BRAIN ISCHEMIA; CLINICAL TRIAL (TOPIC); COMPLICATION; FEMALE; MALE; MIDDLE AGED; STROKE; VERY ELDERLY; VITAMIN B 12 DEFICIENCY;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; MIDDLE AGED; STROKE; VITAMIN B 12; VITAMIN B 12 DEFICIENCY; WARFARIN;

EID: 84929574348     PISSN: 01616412     EISSN: 17431328     Source Type: Journal    
DOI: 10.1179/1743132815Y.0000000026     Document Type: Article

References (17)

1. Hackam DG, Spence JD. Combining multiple approaches for the secondary prevention of vascular events after stroke: a quantitative modeling study. Stroke. 2007;38(6):1881–5.
2. Bogiatzi C, Wannarong T, McLeod AI, Heisel MJ, Hackam DG, Spence JD. SubtyPes of ischAemic stRoKe cLassification systEm (SPARKLE) incorporating measurement of carotid plaque burden: a new validated tool for the classification of ischemic stroke subtypes. Neuroepidemiology. 2014;42:243–51.
3. Ozdemir AO, Tamayo A, Munoz C, Dias B, Spence JD. Cryptogenic stroke and patent foramen ovale: clinical clues to paradoxical embolism. J Neurol Sci. 2008;275(1–2):121–7.
4. Gladstone DJ, Bui E, Fang J, Laupacis A, Lindsay MP, Tu JV, et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke. 2009;40(1):235–40.
5. Spence JD. Stroke: atrial fibrillation, stroke prevention therapy and aging. Nat Rev Cardiol. 2009;6(7):448–50.
6. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983–8.
7. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18): 2370–5.
8. Gladstone DJ, Spring M, Dorian P, Thorpe K, Panzov V, Hall J, et al. Atrial fibrillation detection in patients with cryptogenic stroke: the EMBRACE randomized trial. N Engl J Med. 2014;370(26):2467–77.
9. Spence JD. Atrial fibrillation and stroke prevention: is warfarin still an option? Yes: debate at the controversies in neurology congress, Beijing October 2011. J Neural Transm. 2013; 120(10):1447–51.
10. Gomes T, Mamdani MM, Holbrook AM, Paterson JM, Hellings C, Juurlink DN. Rates of hemorrhage during warfarin therapy for atrial fibrillation. CMAJ. 2013;185(2):E121–7.
11. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (randomized evaluation of longterm anticoagulation therapy). J Am Coll Cardiol. 2014; 63(4):321–8.
12. Goette A. Novel oral anticoagulants for stroke prevention in atrial fibrillation: key trial findings and clinical implications. Trends Cardiovasc Med. 2013;23(4):128–34.
13. Spence JD. Nutrition and stroke prevention. Stroke. 2006; 37(9):2430–5.
14. Spence JD. Nutrition in stroke prevention. US Neurol. 2013;9(1):45–51.
15. Spence JD. Homocysteine-lowering therapy: a role in stroke prevention? Lancet Neurol. 2007;6(9):830–8.
16. Spence JD, Stampfer MJ. Understanding the complexity of homocysteine lowering with vitamins: the potential role of subgroup analyses. JAMA. 2011;306(23):2610–1.
17. Spence JD. B vitamin therapy for homocysteine: renal function and vitamin B12 determine cardiovascular outcomes. Clin Chem Lab Med. 2013;51(3):633–7.